CG Oncology (NASDAQ:CGON) Hits New 12-Month High - Here's Why
CG Oncology (NASDAQ:CGON) recently reached a new 52-week high of $57.92, driven by positive analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $68.58. Despite insider selling by Director James Mulay, who sold 11,145 shares in January, institutional investors have increased their holdings, now owning 26.56% of the company. The biopharmaceutical company focuses on developing novel antibody-based immunotherapies for solid tumor cancers.
CG Oncology stock hits all-time high at 57.92 USD
CG Oncology's stock has reached an all-time high of $57.92, reflecting a 107.15% appreciation over the last year, valuing the company at $4.55 billion. Despite this surge, InvestingPro analysis suggests the stock might be overvalued. The company recently increased its stock offering to $550 million and accelerated its Phase 3 PIVOT-006 clinical trial timeline, leading to raised price targets from Truist Securities and Morgan Stanley.
CG Oncology stock hits all-time high at 57.92 USD
CG Oncology Inc.'s stock reached an all-time high of $57.92, appreciating by 107.15% over the past year and 121% in six months, largely due to investor confidence, increased stock offering, and accelerated clinical trial timelines. Despite this surge, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value. Analysts from Truist Securities and Morgan Stanley have raised their price targets due to the company's strategic advancements and promising trial progress.
CG Oncology stock hits all-time high at 57.92 USD
CG Oncology Inc.'s stock reached an all-time high of $57.92 USD, reflecting a 107.15% appreciation over the past year and a 121% return in six months, valuing the company at $4.55 billion USD. This surge is driven by investor confidence, an increased stock offering of $550 million, and an accelerated timeline for its Phase 3 PIVOT-006 clinical trial, with topline data now expected in the first half of 2026. Despite this, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value.
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, Protara Therapeutics, Binhui Biopharmaceutical
The Muscle Invasive Bladder Cancer (MIBC) market is projected for rapid expansion by 2034, driven by an increasing prevalence of the disease, new premium-priced treatment options, and a robust pharmaceutical pipeline. Key market players like CG Oncology, Pfizer, and Janssen R&D are developing advanced therapies, including PD-1 inhibitors and antibody-drug conjugates, that are transforming treatment landscapes, particularly for cisplatin-ineligible patients. Despite challenges like treatment complexity and high costs, significant clinical trial activity and biomarker-driven approaches are expected to fuel future growth.
CenterBook Partners LP Has $15.92 Million Stake in CG Oncology, Inc. $CGON
CenterBook Partners LP significantly increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 52% in the third quarter, bringing its total holding to 395,340 shares valued at $15.92 million. This move positions CG Oncology as the firm's 24th largest holding, amidst broad bullish sentiment from Wall Street analysts who maintain a "Moderate Buy" consensus rating with an average price target of $68.58. The company's stock recently opened at $53.87, reflecting a market valuation of $4.35 billion, while also noting a director's recent share sale.
CG Oncology, Inc. (CGON) Stock Analysis: A 55% Upside Potential In The Biotech Sector
CG Oncology, Inc. (CGON) is a biotechnology company focused on bladder-sparing therapeutics for bladder cancer. Analysts are bullish on the stock, with an average target price suggesting a 55.06% upside, driven by its innovative pipeline and strong revenue growth of 3,774.40%. Despite current profitability challenges (negative EPS and ROE), the company's strong technical indicators and strategic focus on unmet medical needs in oncology position it for significant future growth.
Did Faster PIVOT-006 Readout and Enlarged ATM Offering Just Shift CG Oncology's (CGON) Investment Narrative?
CG Oncology's investment narrative is shifting due to an accelerated timeline for PIVOT-006 trial results and an expanded US$550 million at-the-market offering. While the faster readout fuels analyst optimism and provides financial flexibility, it also highlights execution and financing risks, including potential dilution. Investors should consider multiple perspectives, as a single fair value estimate is significantly higher than current trading prices, indicating potential undervaluation but also the importance of PIVOT-006 execution.
RBC Capital Sticks to Their Buy Rating for CG Oncology, Inc. (CGON)
RBC Capital maintained a Buy rating on CG Oncology, Inc. (CGON) with a price target of $73.00, according to analyst Leonid Timashev. This comes as the company reported a quarterly revenue of $1.67 million and a GAAP net loss of $43.81 million for the quarter ending September 30. The analyst consensus on CG Oncology, Inc. is a Strong Buy with an average price target of $80.55.
CG Oncology stock price target raised to $75 from $66 at Truist Securities
Truist Securities has raised its price target for CG Oncology (NASDAQ: CGON) to $75 from $66, maintaining a Buy rating. This adjustment follows the firm's increased peak sales estimate for Creto in non-muscle invasive bladder cancer (IR NMIBC) to $1.8 billion and the accelerated timeline for the PIVOT-006 trial results, now expected in the first half of 2026. The analyst firm highlighted the large addressable market and Creto's advanced position.
Truist Financial Boosts CG Oncology (NASDAQ:CGON) Price Target to $75.00
Truist Financial has increased its price target for CG Oncology (NASDAQ:CGON) to $75.00 from $66.00, maintaining a "buy" rating and suggesting a 46.8% upside. Other analysts have also set high price targets, with an average of $68.58 across firms. Despite an unprofitable status and recent insider share sales, the company's stock trades around $51.08 with a market cap of $4.12 billion.
CG Oncology stock price target raised to $75 from $66 at Truist Securities
Truist Securities has raised its price target for CG Oncology (NASDAQ:CGON) to $75 from $66, maintaining a Buy rating. This increase is driven by an updated market analysis and the upcoming disclosure of topline results from the PIVOT-006 trial in the first half of 2026, which targets a large addressable market in bladder cancer. The firm increased its peak sales estimate for Creto in IR NMIBC to $1.8 billion from $1.4 billion, reflecting its strong positioning.
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages
CG Oncology, Inc. (NASDAQ:CGON) has received a consensus "Moderate Buy" rating from fourteen brokerages, with an average one-year price target of $67.83. Several firms, including Piper Sandler, Truist Financial, Goldman Sachs, and Guggenheim, recently raised their price targets for CGON. Despite some insider selling, company insiders own 7.40% and institutions own 26.56% of the stock, which is currently trading around $54.34.
CG Oncology, Inc. (NASDAQ:CGON) Sees Large Decline in Short Interest
CG Oncology, Inc. (NASDAQ:CGON) experienced a significant 27.3% decline in short interest during January, reaching 9,387,150 shares as of January 15th. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $67.83, and multiple firms have recently increased their price objectives. Despite recent insider stock sales, institutional investors have been adjusting their positions, and the company reported quarterly earnings meeting analyst expectations while exceeding revenue forecasts.
Is BOND-003’s Phase 3 Progress Reshaping The Investment Case For CG Oncology (CGON)?
CG Oncology is gaining attention as its flagship BOND-003 therapy progresses through phase 3 trials for high-risk bladder cancer, aiming to offer a bladder-sparing treatment option. The company's investment narrative focuses on cretostimogene grenadenorepvec becoming a new standard of care, with PIVOT-006 topline data expected in the first half of 2026. Despite elevated expectations and stock volatility, CG Oncology remains a single-asset, pre-commercial biotech with ongoing losses and execution risks related to funding and profitability.
Is BOND-003’s Phase 3 Progress Reshaping The Investment Case For CG Oncology (CGON)?
CG Oncology's flagship BOND-003 therapy is advancing in phase 3 trials for high-risk BCG-unresponsive non-muscle invasive bladder cancer, aiming for a bladder-sparing treatment. While the expected topline data for PIVOT-006 in H1 2026 adds a near-term catalyst, the company remains a single-asset, pre-commercial biotech with minimal revenue and ongoing losses, maintaining execution and funding risks. Despite a strong stock performance and some investors seeing large upside, its shares might still be trading above fair value, highlighting a need for investors to consider the binary outcomes of its clinical trials and cash needs.
Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON)
Healthcare analysts are optimistic about Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON), and Altimmune (ALT). H.C. Wainwright maintained a Buy rating for Protagonist Therapeutics with an $80 price target, and for CG Oncology, Inc. with a $75 price target, and for Altimmune with a $12 price target. All three companies have a consensus analyst rating of Strong Buy, indicating expected upside from current levels.
CG Oncology stock hits all-time high at 57.4 USD By Investing.com
CG Oncology Inc. has seen its stock reach an all-time high of $57.4 USD, marking an 87.02% increase over the past year. Analysts have issued a "strong buy" consensus with a price target of $108, spurred by strategic initiatives, an increased stock offering, and an accelerated clinical trial timeline for their PIVOT-006 study. However, the stock's RSI suggests it may be in overbought territory, and current valuation metrics indicate it might be trading above its Fair Value.
CG Oncology (NASDAQ:CGON) Sets New 52-Week High - Should You Buy?
CG Oncology (NASDAQ:CGON) recently reached a new 52-week high of $57.62, with analysts giving it a "Moderate Buy" rating and an average price target of $67.83. Despite the company being unprofitable with low revenue, institutional investors have increased their stakes, though some directors have sold shares. The article discusses analyst ratings, price performance, insider transactions, and institutional inflows/outflows for the biotech company.
CGON: RBC Capital Raises Price Target to $73, Maintains Outperfo
RBC Capital has increased its price target for CG Oncology (CGON) to $73 from $61, maintaining an "Outperform" rating, following consistent positive adjustments from other analysts. CG Oncology is a biopharmaceutical company focused on developing therapies for bladder cancer. The average target price from 12 analysts is $79.33, suggesting an upside of 38.54% from its current price.
CG Oncology stock hits all-time high at 57.4 USD
CG Oncology Inc. (CGON) stock has reached an all-time high of $57.40, marking an 87.02% increase over the past year. This growth is attributed to strong investor confidence and strategic company initiatives, including an accelerated clinical trial timeline and an increased stock offering. Analysts maintain a "Buy" consensus with price targets up to $108.
Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline
CG Oncology (CGON) has seen its valuation come under scrutiny following the accelerated timeline for its PIVOT-006 Phase 3 trial. Despite a significant 88.20% share price return over the past year, the company's Price to Book ratio of 6.4x is considered expensive compared to the broader US biotech industry. However, a Discounted Cash Flow (DCF) model suggests the stock is trading at a substantial discount to its estimated fair value, indicating a potential investment opportunity.
Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline
CG Oncology (CGON) is under evaluation following the acceleration of its PIVOT-006 Phase 3 trial timeline. The stock has shown strong recent performance, with a 30-day return of 40.23% and a 1-year return of 88.20%. Despite a seemingly expensive Price-to-Book ratio of 6.4x compared to the broader US biotech group, a Discounted Cash Flow (DCF) model suggests the shares could be significantly undervalued, trading about 81.1% below an estimated fair value of US$289.42.
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Disc Medicine (IRON)
Two healthcare companies, CG Oncology, Inc. (CGON) and Disc Medicine (IRON), recently received bullish sentiments from analysts. Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on CGON with a $65.00 price target, while Truist Financial's Danielle Brill maintained a Buy rating on IRON. Both stocks hold a "Strong Buy" consensus rating among analysts, with significant upside potential from current levels.
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why
CG Oncology (CGON) shares surged nearly 32% in the past week after the company announced it expects to release top-line data from its phase III PIVOT-006 study earlier than projected, in the first half of 2026. This accelerated timeline and promising late-stage data for its investigational immunotherapy, cretostimogene grenadenorepvec, have increased investor confidence, especially considering the lack of FDA-approved therapies for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). The company is also working on a rolling biologics license application for another bladder cancer indication.
CG Oncology Expands At-The-Market Equity Offering Capacity
CG Oncology (CGON) has increased its At-The-Market equity offering capacity to $550 million, seeking to raise an additional $300 million through an amended prospectus filed with the SEC. This expansion, facilitated by Jefferies LLC, aims to provide greater capital-raising flexibility for future needs but could dilute existing shareholders if fully utilized. Analysts currently rate CGON as a Buy with an $82.00 price target, although TipRanks' AI Analyst, Spark, assigns a Neutral score due to mixed financial performance including heavy losses despite a strong balance sheet.
CG Oncology Expands At-The-Market Equity Offering Capacity
CG Oncology, Inc. (CGON) has expanded its at-the-market equity offering capacity from $250 million to $550 million through an amended prospectus filed with the SEC. This move allows the company to raise an additional $300 million, supporting future financing needs and strategic initiatives, though it could dilute existing shareholders. While analysts rate CGON a "Buy" with an $82.00 price target, TipRanks' AI Analyst Spark gives it a "Neutral" score due to strong balance sheet but ongoing losses and cash burn.
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026
CG Oncology Inc. has accelerated the release of topline data for its PIVOT-006 clinical trial to the first half of 2026, leading to a significant 21.8% surge in its stock price. The trial focuses on non-muscle invasive bladder cancer, with analysts projecting further stock price increases based on the company's progress and the potential for a new treatment standard. This acceleration, driven by rapid enrollment, reflects strong market confidence and could enhance the company's competitive position and financing capabilities.
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why
Shares of CG Oncology (CGON) surged almost 32% in a week after the company announced it expects to report top-line data from its phase III PIVOT-006 study nearly a year earlier than projected, in the first half of 2026. This acceleration, driven by early patient enrollment, and positive late-stage data from its BOND-003 study, has significantly boosted investor confidence regarding regulatory approval for its bladder cancer treatment, cretostimogene grenadenorepvec. The company's investigational oncolytic immunotherapy is being evaluated for various bladder cancer indications, with no FDA-approved therapies currently available for certain patient groups.
Mulay, James sells CG Oncology (CGON) shares for $584,798
Director James Mulay of CG Oncology (NASDAQ:CGON) recently sold 11,145 shares of the company's common stock for $584,798 on January 9, 2026, while also exercising options to acquire an equal number of shares. The sale occurred amidst significant stock momentum, with CGON showing a 24% return last week and an 88% gain over the past year, though InvestingPro views the stock as overvalued. The company also filed an amendment to increase its at-the-market common stock offering to $550 million and accelerated its Phase 3 PIVOT-006 clinical trial timeline, leading to raised analyst price targets.
CG Oncology Files Amendment to Increase Stock Offering
CG Oncology (CGON) recently filed an amendment to increase its stock offering to $550 million, representing a $300 million increase from the previous amount. This amendment supplements a March 2025 prospectus and includes an opinion from Cooley LLP regarding share validity. The original SEC filing is dated January 13, 2026.
James Mulay Sells 11,145 Shares of CG Oncology (NASDAQ:CGON) Stock
CG Oncology (NASDAQ:CGON) Director James Mulay sold 11,145 shares of the company's stock on January 9th for a total value of $584,778.15. The transaction was disclosed in an SEC filing, revealing the shares were sold at an average price of $52.47. The stock experienced a slight dip during mid-day trading but has a "Moderate Buy" consensus rating from analysts with an average target price of $65.58.
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages
Fourteen brokerages have issued a consensus "Moderate Buy" rating for CG Oncology, Inc. (NASDAQ:CGON), with an average 12-month price target of $61.42. The company recently reported Q3 earnings per share of ($0.57) on $0.16 million in revenue, meeting analyst estimates. Insider and institutional ownership stands at approximately 7.4% and 26.56%, respectively, with recent insider selling noted.
CG Oncology Expedites PIVOT-006 Phase 3 Topline Data Readout In Intermediate-Risk NMIBC To H1 2026
CG Oncology, Inc. announced an accelerated timeline for their PIVOT-006 Phase 3 topline data readout, now expected in the first half of 2026, nearly a year ahead of schedule. This acceleration was due to rapid patient enrollment in the study for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). The company aims to bring a potential new treatment option to market for IR NMIBC, for which there are currently no FDA-approved therapies.
CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 Timeline - Has The Bull Case Changed?
CG Oncology's stock surged by 29.7% after the company announced an accelerated timeline for the topline data release of its Phase 3 PIVOT-006 trial to the first half of 2026, nearly a year earlier than expected due to rapid patient enrollment. This acceleration, while sharpening the investment calendar, also concentrates risk as the company remains unprofitable and is not forecasted to reach profitability in the next three years, despite the market's positive reaction. The article emphasizes that the investment narrative for CG Oncology hinges on the success of its bladder-sparing therapy, cretostimogene, in achieving regulatory approval and commercial viability.
CG Oncology Gains Momentum as Price Targets and Investor Confidence Rise
CG Oncology (CGON) stock has surged by 25.72% due to positive clinical trial results and increased investor confidence. Major financial institutions like Morgan Stanley, Wedbush, and BofA have raised their price targets and issued "Overweight" or "Buy" ratings, signaling strong growth expectations for the company's innovative oncolytic virus treatment. Despite some current profitability struggles, CG Oncology shows strong short-term liquidity and a minimal debt load, positioning it for potential long-term momentum.
CG Oncology, Inc. Announces Expedited Timeline for PIVOT-006 Phase 3 Data
CG Oncology, Inc. has announced an expedited timeline for its PIVOT-006 Phase 3 topline data for intermediate-risk NMIBC, now expected in the first half of 2026, nearly a year ahead of schedule. This trial is the first Phase 3 study for this patient group, with over 360 patients enrolled across 90+ sites. The announcement also highlighted promising results from BOND-003 Cohort P and CORE-008 Cohort A in NMIBC patients.
Bladder cancer trial to deliver key results nearly a year early
CG Oncology (NASDAQ: CGON) announced that topline Phase 3 data from its PIVOT-006 study for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) is now expected in 1H 2026, nearly a year ahead of schedule due to rapid patient enrollment. The trial compares cretostimogene grenadenorepvec against surveillance in over 360 patients and is the first Phase 3 randomized study for this patient population. Following the announcement, CGON's stock surged by 28.98%, reflecting a strong positive market reaction.
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
CG Oncology has announced an expedited timeline for the topline data readout of its PIVOT-006 Phase 3 clinical trial, now expected in the first half of 2026, nearly a year ahead of schedule. The trial evaluates cretostimogene monotherapy for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), a population with over fifty thousand patients in the US alone. This accelerated timeline is due to the rapid and unprecedented early completion of enrollment for the study, which is the first Phase 3 randomized trial in this patient population.
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
CG Oncology, Inc. announced that its Chairman & Chief Executive Officer, Arthur Kuan, and President & Chief Operating Officer, Ambaw Bellete, will present at the 4 4th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will cover the company's work as a late-stage clinical biopharmaceutical company focused on bladder-sparing therapeutics for bladder cancer patients. Interested parties can access a live audio webcast of the presentation and its replay on the company's investor relations website.
CG Oncology Announces Participation in 44th Annual J.P. Morgan Healthcare Conference
CG Oncology, a biopharmaceutical company focusing on bladder cancer therapies, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. Chairman and CEO Arthur Kuan and President and COO Ambaw Bellete will discuss the company's bladder-sparing therapeutics. The presentation will be webcast live and available for replay on the company's website.
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
CG Oncology, Inc. announced that its Chairman & Chief Executive Officer, Arthur Kuan, and President & Chief Operating Officer, Ambaw Bellete, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 15, 2026, at 8:15 am PT / 11:15 am ET. A live audio webcast will be accessible from the Investor Relations section of the company's website.
Voya Investment Management LLC Has $1.93 Million Stock Holdings in CG Oncology, Inc. $CGON
Voya Investment Management LLC significantly increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 217.6% in the third quarter, bringing its total holdings to 47,986 shares valued at approximately $1.93 million. This comes as other institutional investors have also adjusted their positions, and despite recent insider selling, Wall Street analysts maintain a "Moderate Buy" rating for CG Oncology with an average price target of $60.58. The clinical-stage biopharmaceutical company focuses on novel antibody-based immunotherapies for solid tumor cancers.
CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC Data - What's Changed
CG Oncology (CGON) recently released positive topline data from its BOND-003 and CORE-004 trials for cretostimogene in non-muscle invasive bladder cancer (NMIBC), demonstrating encouraging efficacy and a consistent safety profile. Despite these strong results, the company's stock has fallen 8.7%, likely due to market debates on durability and competitive positioning. While the data strengthens CG Oncology's investment narrative for future Phase 3 readouts, the company remains largely pre-revenue and loss-making, with significant clinical, regulatory, and financing risks.
SUO-CTC CG Oncology NMIBC Research Fellowship
The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) and CG Oncology, Inc. have launched an annual research fellowship to support early-career investigators in Non-Muscle Invasive Bladder Cancer (NMIBC). Two awards of up to $50,000 each are available for one-year basic, translational, or clinical research projects, with applications due by February 27, 2026. Awardees are expected to present their work at the SUO meeting at the AUA.
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) and CG Oncology have announced their second annual NMIBC Research Fellowship, aiming to support clinical cancer investigators focused on non-muscle invasive bladder cancer. Two recipients will each receive a $50,000 grant, with applications due by February 27, 2026. This initiative seeks to advance research and improve treatments for bladder cancer, with presentations of completed projects at the American Urological Association annual meeting.
CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Moderate Buy" by Brokerages
CG Oncology, Inc. (NASDAQ:CGON) has received an average "Moderate Buy" rating from fifteen brokerages, with a consensus 12-month price target of $60.58. Despite this positive outlook and several recent price target raises, insiders have been net sellers, offloading approximately $1.89 million worth of shares. The company remains unprofitable, reflected in its current stock price of $40.94 and a negative EPS.
CG Oncology appoints Rossi to its Board of Directors
CG Oncology has announced the appointment of Arthur T. Rossi to its Board of Directors. Rossi brings over 30 years of experience in the biopharmaceutical industry, with a strong background in financial and operational leadership, which will be valuable as CG Oncology advances its clinical programs.
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases Shares of 26,000 CG Oncology, Inc. $CGON
OCONNOR, a unit of UBS Asset Management, recently initiated a position in CG Oncology (NASDAQ: CGON) by purchasing 26,000 shares valued at approximately $676,000. Other institutional investors like Tema ETFs and Saturn V Capital Management also increased their stakes, bringing total institutional ownership to around 26.56%. Despite negative profitability and recent insider selling, Wall Street analysts maintain a "Moderate Buy" rating with a consensus price target of $60.58.
Wedbush initiates coverage on CG Oncology stock with Outperform rating
Wedbush has initiated coverage on CG Oncology (NASDAQ: CGON) with an Outperform rating and a $70.00 price target, citing its cretostimogene grenadenorepvec treatment for non-muscle invasive bladder cancer. The firm anticipates a Biologics License Application submission in 2026, which, alongside clinical readouts, is expected to increase share value. While CG Oncology has strong financial flexibility, analysts do not expect profitability this year.
